Lantern Pharma Inc. (Nasdaq: Ltrn)

Lantern Pharma Inc. (Nasdaq: Ltrn) company information, Employees & Contact Information

Explore related pages

Lantern Pharma Inc. (Nasdaq: Ltrn) email format Lantern Pharma Inc. (Nasdaq: Ltrn) management contacts

Related company profiles:

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

Company Details

Employees
29
Founded
-
Address
1920 Mckinney Ave, Dallas,tx 75201,united States
Phone
972-277-1136
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
lanternpharma.com
Keywords
Biotechnology, Cancer Drug Development, Precision Medicine, Biomarkers, Genetic Screen, Companion Diagnostics, PrecisionOncology, Artificial Intelligence, Patient Stratification, Drug Rescue, Drug Repurposing.
HQ
Dallas, TX
Competitors
Taysha Gene Therapies, Biora Therapeutics, BioNTX, Starlight Therapeutics, ImmuneSensor Therapeutics, Gradalis, Inc., Nanoscope Therapeutics Inc., Colossal Biosciences, Santa Cruz Biotechnology (SCBT), BioLabs Pegasus Park - North Texas.
Looking for a particular Lantern Pharma Inc. (Nasdaq: Ltrn) employee's phone or email?

Lantern Pharma Inc. (Nasdaq: Ltrn) Questions

News

Lantern Pharma (NASDAQ: LTRN) to present Oct 30 at ThinkEquity, 11:30 a.m. ET in New York - Stock Titan

Lantern Pharma (NASDAQ: LTRN) to present Oct 30 at ThinkEquity, 11:30 a.m. ET in New York Stock Titan

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - Yahoo Finance

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ Yahoo Finance

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Yahoo Finance

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment Yahoo Finance

FDA Green Lights Lantern Pharma's Breakthrough Brain Cancer Drug Trial Targeting $5B GBM Market - Stock Titan

FDA Green Lights Lantern Pharma's Breakthrough Brain Cancer Drug Trial Targeting $5B GBM Market Stock Titan

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors - Yahoo Finance

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors Yahoo Finance

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years - Business Wire

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years Business Wire

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates Business Wire

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Yahoo Finance

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality Yahoo Finance

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial Business Wire

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Yahoo Finance

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Yahoo Finance

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - Business Wire

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy Business Wire

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - Yahoo Finance

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need Yahoo Finance

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors - Business Wire

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors Business Wire

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Newswire.com

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Newswire.com

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - Business Wire

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers Business Wire

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism - Business Wire

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism Business Wire

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Business Wire

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort Business Wire

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers - Business Wire

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers Business Wire

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - FinancialContent

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. FinancialContent

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers - Business Wire

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers Business Wire

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform - PR Newswire

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform PR Newswire

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 - PR Newswire

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 PR Newswire

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S - PR Newswire

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S PR Newswire

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting - Lelezard

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting Lelezard

Oncotarget: Retaining nanomolar potency in lung cancer with therapy-refractory mutations - EurekAlert!

Oncotarget: Retaining nanomolar potency in lung cancer with therapy-refractory mutations EurekAlert!

Companies like Lantern Pharma Inc. (Nasdaq: Ltrn)

Gradalis, Inc. logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Gradalis, Inc.

25
Starlight Therapeutics logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Starlight Therapeutics

NA
Colossal Biosciences logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Colossal Biosciences

202
Biora Therapeutics logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Biora Therapeutics

49
ImmuneSensor Therapeutics logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Immunesensor Therape...

11
Nanoscope Therapeutics Inc. logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Nanoscope Therapeuti...

48
Taysha Gene Therapies logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Taysha Gene Therapies

115
BioLabs Pegasus Park - North Texas logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Biolabs Pegasus Park...

4
Santa Cruz Biotechnology (SCBT) logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Santa Cruz Biotechno...

165
BioNTX logo - Similar company to Lantern Pharma Inc. (Nasdaq: Ltrn)

Biontx

14

Top Lantern Pharma Inc. (Nasdaq: Ltrn) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant